Skip to main content
DNTH
NASDAQ Life Sciences

菊花石杉药业以每股81美元定价扩大规模的6.25亿美元发行

feedReported by Reuters
Sentiment info
Negative
Importance info
8
Price
$87.5
Mkt Cap
$3.757B
52W Low
$13.365
52W High
$86.97
Market data snapshot near publication time

summarizeSummary

菊花石杉药业已经以每股81.00美元的价格定价了扩大规模的公开发行，发行7,313,582股，籌集約6.25亿美元。这次融资跟随公司最近在3月9日关于其第三期CAPTIVATE试验中claseprubart用于CIDP的早期“GO决定”的积极公告，这是一个重大的催化剂。虽然资本增加为其主要资产的持续开发提供了大量资金，但该发行具有高度稀释性，并且以低于当前87.50美元的市场价格折价发行。这种显著的稀释和折价可能会在短期内对股票施加下行压力，尽管从长远来看，加强的财务资源将带来益处。

在该公告发布时，DNTH的交易价格为$87.50，交易所为NASDAQ，所属行业为Life Sciences，市值约为$37.6亿。 52周交易区间为$13.37至$86.97。 这则新闻被评估为消极市场情绪，重要性评分为8/10。 来源：Reuters。

show_chartPrice Chart

Share this article

Copied!

feed DNTH - Latest Insights

DNTH
Mar 26, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Dianthus Therapeutics Secures $676M in Offering, Receives Favorable FDA Feedback for Claseprubart Trials
Sentiment: Positive
View Wiseek Article
DNTH
Mar 13, 2026, 8:40 PM EDT
Source: Wiseek News
Importance Score:
8
Dianthus CEO, Key Executives Liquidate All Direct Stock Holdings
Sentiment: Negative
View Wiseek Article
DNTH
Mar 12, 2026, 7:20 AM EDT
Filing Type: 8-K
Importance Score:
8
Dianthus Therapeutics Finalizes $673.5M Upsized Public Offering, Including Full Underwriter Option Exercise
Sentiment: Neutral
View Wiseek Article
DNTH
Mar 11, 2026, 5:28 PM EDT
Filing Type: 424B5
Importance Score:
8
Dianthus Therapeutics Prices $625M Public Offering at $81.00 Per Share, Extending Cash Runway
Sentiment: Neutral
View Wiseek Article
DNTH
Mar 10, 2026, 10:56 PM EDT
Source: Reuters
Importance Score:
8
Dianthus Therapeutics Prices Upsized $625M Offering at $81/Share
Sentiment: Negative
View Wiseek Article
DNTH
Mar 10, 2026, 9:54 PM EDT
Filing Type: S-3MEF
Importance Score:
8
Dianthus Therapeutics Upsizes Shelf Registration by $120M, Increasing Capital Raise Capacity to $720M
Sentiment: Neutral
View Wiseek Article
DNTH
Mar 09, 2026, 5:25 PM EDT
Filing Type: 424B5
Importance Score:
9
Dianthus Therapeutics Details Proposed $400M Public Offering Following Positive Phase 3 Trial Results
Sentiment: Neutral
View Wiseek Article
DNTH
Mar 09, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
Dianthus Therapeutics Commences $400M Public Offering Following Positive Phase 3 Trial News
Sentiment: Negative
View Wiseek Article
DNTH
Mar 09, 2026, 7:21 AM EDT
Filing Type: 10-K
Importance Score:
9
Dianthus Therapeutics Reports Early Phase 3 Success for Claseprubart in CIDP, Extends Cash Runway
Sentiment: Positive
View Wiseek Article
DNTH
Mar 09, 2026, 7:19 AM EDT
Filing Type: 8-K
Importance Score:
9
Dianthus Therapeutics Achieves Early GO Decision in Pivotal Phase 3 CIDP Trial for Claseprubart
Sentiment: Positive
View Wiseek Article